Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.
Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
